Pioglitazone as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Treatment With Gemcitabine

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting

Study NCT00867126 Information provided by National Cancer Institute (NCI)

First Received on March 20, 2009. Last Updated on April 2, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Pancreatic Cancer

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

Additional drug interventions recognized in this trial

Gemcitabine
Pioglitazone

More general drug interventions related to this trial

Sponsors listed in this trial